Table 2.

Cell therapy studies in mice models of chagasic cardiomyopathy.

Reference	Cell type/source	Route	Main results	Observation time	Mouse strain
Soares et al., 2004	Bone marrow mononuclear cells (BM-MNC)	I.V.	Reduction inflammatory cell number and fibrosis percentage	6 months	BALB/c and C57BL/6
Goldenberg et al., 2008	Bone marrow mononuclear cells (BM-MNC)	I.V.	Reduction of right ventricular dilation	3 months	C-129
Soares et al., 2011	Bone marrow mononuclear cells (BM-MNC)	I.V.	Decreased expression of genes related with inflammation and fibrosis in the heart	2 months	C57BL/6
Jasmin et al., 2012	Bone marrow mesenchymal stem cells (BM-MSC)	I.V.	Decreased right ventricular internal diameter	15-30 days	CD-1
Mello et al., 2015	Adipose derived mesenchymal stem cells (AD-MSC)	I.P.	Reduction of parasitemia, cardiac inflammation, parasitism and fibrosis Right ventricular dilation prevention	30 and 60 days	CD-1
Larocca et al., 2013	Adipose-derived mesenchymal stem cells (AD-MSC)	I.P.	Reduction of inflammation and fibrosis	2 months	C57BL/6
Silva et al., 2014	Cardiac mesenchymal stem cells (C-MSC)	I.M.	Reduction of cardiac inflammation and TNF expression	2 months	C57BL/6
Silva et al., 2018	Mesenchymal stem cells overexpressing G-CSF	I.P.	Reduction of inflammation and fibrosis; TNF and IFN-γ modulation; Increased IL-10 expression	7, 30 and 60 days	C57BL/6
Silva et al., 2018	Mesenchymal stem cells overexpressing IGF-1	I.V.	Reduction of inflammation, fibrosis and TNF expression.	2 months	C57BL/6
Santos et al., 2020	tolerogenic dendritic cells	I.P.	Reduction of inflammation, fibrosis and increased Treg cells and IL-10	3 months	C57BL/6

I.M., intramyocardial route; I.V., intravenous route; I.P., intraperitoneal route.